CD28 and CTLA4 are T cell coreceptors that competitively engage B7 ligands CD80 and CD86 to control adaptive immune responses. While the role of CTLA4 in restraining CD28 costimulatory signaling is well-established, the mechanism has remained unclear. Here, we report that human T cells acquire antigen-presenting-cell (APC)-derived B7 ligands and major histocompatibility complex (MHC) via trogocytosis through CD28:B7 binding. Acquired MHC and B7 enabled T cells to autostimulate, and this process was limited cell-intrinsically by CTLA4, which depletes B7 ligands trogocytosed or endogenously expressed by T cells through cis-endocytosis. Extending this model to the previously proposed extrinsic function of CTLA4 in human regulatory T cells (Treg), we show that blockade of either CD28 or CTLA4 attenuates Treg-mediated depletion of APC B7, indicating that trogocytosis and CTLA4-mediated cis-endocytosis work together to deplete B7 from APCs. Our study establishes CTLA4 as a cell-intrinsic molecular sink that limits B7 availability on the surface of T cells, with implications for CTLA4-targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103642 | PMC |
| http://dx.doi.org/10.1084/jem.20221391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers.
J Immunother Cancer
January 2025
Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Background: Human papillomavirus (HPV)-driven cancers include head and neck squamous cell carcinoma and cervical cancer and represent approximately 5% of all cancer cases worldwide. Standard-of-care chemotherapy, radiotherapy, and immune checkpoint inhibitors (ICIs) are associated with adverse effects and limited responses in patients with HPV-driven cancers. The integration of targeted therapies with ICIs may improve outcomes.
View Article and Find Full Text PDFUnleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity.
Int Immunopharmacol
January 2025
Department of Oral Biology, School and Hospital of Stomatology, Jilin University, Changchun, China; Key Laboratory of Tooth Development and Bone Remodeling of Jilin Province, School and Hospital of Stomatology, Jilin University, Changchun, China. Electronic address:
Article Synopsis
- Regulatory T (Treg) cells are a type of immunosuppressive CD4 T cells that can hinder anti-tumor immune responses, creating challenges in cancer treatment.
- Various immune checkpoints (like PD-1/PD-L1, CTLA-4) play critical roles in managing Treg cell activity and proliferation in tumors, impacting overall tumor immunity.
- Targeting these checkpoints and combining therapies, such as immune checkpoint blockade and CCR8-targeted treatments, may enhance anti-tumor immunity and improve results for cancer patients.
Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein.
Cancer Commun (Lond)
December 2024
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P. R. China.
Background: The majority of patients with prostate cancer (PCa) exhibit intrinsic resistance to immune checkpoint blockade (ICB) following radiotherapy (RT). This resistance is generally attributed to the limited antigen presentation of heterogeneous cells within tumors. Here, we aimed to isolate and characterize these diverse subgroups of tumor post-RT to understand the molecular mechanisms of their resistance to ICB.
View Article and Find Full Text PDFTemozolomide overcoming resistance to immune checkpoint inhibitors in relapsed/refractory metastatic melanoma? Insights from a single center series.
J Oncol Pharm Pract
November 2024
Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
There is a need to develop more effective salvage therapies for patients with relapsed melanoma of the skin. Research has shown that chemotherapy-induced cancer cell death may increase immunogenic antigen exposure, or upregulation of co-inhibitory ligands such as PD-L1, thereby augmenting immune checkpoint inhibitor (ICI) efficacy. In addition, chemotherapy preconditioning may lead to depletion of Tregs, known to suppress immune anti-melanoma responses.
View Article and Find Full Text PDFNatural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases.
J Immunother Cancer
November 2024
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
Article Synopsis
- Brain metastases significantly impact patients with metastatic melanoma, with a severe prognosis and limited durable responses to combined immune checkpoint inhibitors like PD-1 and CTLA-4, especially in symptomatic cases.
- Research shows that natural killer (NK) cells play a crucial role in enhancing the effectiveness of immune therapy against brain tumors, while their depletion leads to poorer outcomes and decreased CD8+ T cell levels within tumors.
- The study reveals that the effectiveness of PD-1/CTLA-4 blockade is dependent on chemokine-driven trafficking of CD8+ T cells to intracranial tumors, highlighting the complexity of immune responses in the brain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!